Non-Viral Gene Therapies Gain Momentum as Safety Concerns Drive Industry Shift from Viral Vectors
核心洞察
Gene therapy developers are increasingly exploring non-viral delivery methods following safety concerns with viral vectors, including patient deaths linked to liver toxicity in studies by Sarepta, Pfizer, Intellia (搜索), Rocket (搜索), and Capsida (搜索).
Lipid nanoparticles (LNPs), Sleeping Beauty transposon systems, and electro-transfection are emerging as promising non-viral alternatives that may offer improved safety profiles and reduced manufacturing complexity.
While experts view non-viral approaches as potentially representing the future of gene therapy, they expect these methods to coexist with viral vectors rather than completely replace them in the near term.
Gene therapy developers are pivoting toward non-viral delivery systems as mounting safety concerns with viral vector-based therapies prompt a strategic reassessment across the industry. Recent patient deaths linked to viral gene therapies have accelerated interest in alternative approaches that may offer improved safety profiles while addressing manufacturing challenges.
The shift comes amid heightened scrutiny of viral vector safety, exemplified by Sarepta Therapeutics' Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy (搜索), which drew FDA attention after being linked to two patient deaths from liver toxicity. Similar safety signals have emerged from gene therapy studies conducted by Pfizer, Intellia (搜索), Rocket (搜索), and Capsida (搜索), prompting the field to explore new delivery strategies.
Addressing Manufacturing and Safety Challenges
According to Tamas Laufer, an industry-funded PhD student at University College London exploring non-viral gene therapies, these alternative delivery methods could prove instrumental in addressing scalability and commercial sustainability challenges. "Non-viral delivery methods could prove instrumental in addressing these final points, as they will likely be simpler to produce at scale," Laufer explains.
Beyond manufacturing advantages, non-viral systems may overcome genotoxicity and immunogenicity issues sometimes associated with viral alternatives, though Laufer cautions it's too early to make definitive claims as these approaches remain in their infancy. Non-viral systems also offer greater flexibility in payload size, potentially enabling delivery of large genes that are difficult or impossible to deliver using viral vectors.
Ilya Yasny, a partner at LanceBio Ventures (搜索), sees strong potential in non-viral delivery largely because it may help overcome the unpredictability and manufacturing complexity associated with viral vectors. However, industry experts emphasize that precise targeting and further clinical proof remain critical for unlocking the market promise of non-viral approaches.
Lipid Nanoparticles Lead the Charge
Lipid nanoparticles (LNPs) have emerged as a leading non-viral delivery platform, building on their success in COVID-19 mRNA vaccines. Developed in the 20th century by scientists Pieter Cullis, Michael Hope, and Thomas Madden at the University of British Columbia, LNPs form protective layers around nucleic acids, enabling direct delivery of genetic payloads to target cells.
"LNPs hold great potential, but are still at the beginning of the road," Yasny comments. "Sophisticated, viral-like particles that can distribute effectively to target organs other than the liver could also be a game changer."
Venkata Indurthi, CSO at CDMO Aldevron (搜索), notes that LNPs are "more tunable and controllable" than viral vectors, though their use over traditional viral approaches will depend on the specific disease being treated. While no LNP-based traditional gene therapies have received approval, Alnylam Pharmaceuticals (搜索)' Onpattro (patisiran) became the first siRNA delivered via LNP to secure approval in 2018.
According to GlobalData's Pharmaceutical Intelligence Center, most non-viral gene therapies currently in early development employ LNP-based delivery mechanisms.
Emerging Non-Viral Technologies
The Sleeping Beauty transposon approach has captured particular attention for its potential to address manufacturing cost challenges. This method combines a plasmid or minicircle incorporating both a transposon protein and gene of interest with mRNA encoding a transposase enzyme, acting through a "cut-and-paste" approach to enable stable integration of genetic material.
Laufer suggests this system could help bring down manufacturing costs while enabling delivery of larger genetic sequences through precision gene editing techniques like CRISPR-Cas9. However, he cautions that delivery efficiency and expression tend to diminish as sequences get larger.
Electro-transfection represents another promising non-viral approach, using electrical impulses to temporarily open target cell membranes for genetic payload delivery. The technology gained prominence when Vertex and CRISPR Therapeutics secured approval for Casgevy (exagamglogene autotemcel), a CRISPR-based sickle cell disease (搜索) therapy manufactured using electroporation.
PulseSight (搜索) is advancing this approach with its electro-transfected geographic atrophy (搜索) gene therapy PST-611, planned for Phase II trials in summer 2026. CEO Judith Greciet explains that direct DNA plasmid administration into the ciliary muscle overcomes limitations of chemical or viral delivery systems by removing them entirely.
Coexistence Rather Than Replacement
Despite growing enthusiasm for non-viral approaches, experts predict these methods will coexist with viral vectors rather than replace them entirely. Laufer and Indurthi note that both approaches are likely to retain distinct roles in the market given their differing advantages across specific diseases and patient populations.
Indurthi adds an important caveat: viral gene therapy-prompted immunogenicity is not always tied to the viral vector, as this impact can be caused by the nucleic acid itself. This means non-viral systems may not overcome immunogenicity challenges if they're associated with the genetic payload.
Looking ahead, Yasny and Indurthi suggest that non-viral systems could represent "the future" of gene therapy, though they emphasize that further development will be required before this potential can be fully realized. As the field continues to evolve, the focus remains on developing delivery systems that balance efficacy, safety, and commercial viability to bring transformative therapies to patients with complex, hard-to-treat diseases.